Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 1
2020 1
2022 2
2023 2
2024 4
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Citations

3 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
A STING-activating nanovaccine for cancer immunotherapy.
Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, Du M, Huang G, Wang C, Chen X, Porembka MR, Lea J, Frankel AE, Fu YX, Chen ZJ, Gao J. Luo M, et al. Nat Nanotechnol. 2017 Jul;12(7):648-654. doi: 10.1038/nnano.2017.52. Epub 2017 Apr 24. Nat Nanotechnol. 2017. PMID: 28436963 Free PMC article.
The generation of tumour-specific T cells is critically important for cancer immunotherapy. A major challenge in achieving a robust T-cell response is the spatiotemporal orchestration of antigen cross-presentation in antigen-presenting cells with innate stimulation. …
The generation of tumour-specific T cells is critically important for cancer immunotherapy. A major challenge in achieving a r …
STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy.
Nguyen NT, Le XT, Lee WT, Lim YT, Oh KT, Lee ES, Choi HG, Youn YS. Nguyen NT, et al. Bioact Mater. 2024 Sep 6;42:345-365. doi: 10.1016/j.bioactmat.2024.09.002. eCollection 2024 Dec. Bioact Mater. 2024. PMID: 39290338 Free PMC article.
Recently, nanovaccine-based immunotherapy has been robustly investigated due to its potential in governing the immune response and generating long-term protective immunity. ...Type 1 conventional dendritic cell (cDC1) subset is of particular interest due to its pivo …
Recently, nanovaccine-based immunotherapy has been robustly investigated due to its potential in governing the immune response …
Personalized Nanovaccine Based on STING-Activating Nanocarrier for Robust Cancer Immunotherapy.
Li Y, Dong Y, Shen D, Guo Y, Cao Y, Zhang K, Li X, Zhu R, Yi J, Yao X, Dang X, Li R, Zhang Z, Qin Z, Yang W. Li Y, et al. ACS Nano. 2025 Jan 28;19(3):3226-3239. doi: 10.1021/acsnano.4c11014. Epub 2025 Jan 16. ACS Nano. 2025. PMID: 39817337
In vivo studies indicate that the smart nanovaccine dramatically inhibits tumor growth with a long-term immune memory response in both the B16-OVA and EG7-OVA tumor models. ...The rational design provides inspiration for personalized nanovaccine construction via imm …
In vivo studies indicate that the smart nanovaccine dramatically inhibits tumor growth with a long-term immune memory response in bot …
Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapy.
Li Y, Fang M, Yu H, Wang X, Xue S, Jiang Z, Huang Z, Rong S, Wei X, Lu Z, Luo M. Li Y, et al. Nat Commun. 2025 May 23;16(1):4783. doi: 10.1038/s41467-025-59977-8. Nat Commun. 2025. PMID: 40404668 Free PMC article.
Biomimetic nanovaccines employing cancer cell membranes display inherent biocompatibility and stimulate T-cell responses against diverse tumour antigens, though tumours develop multiple mechanisms to reduce antigen presentation. ...Interferon-gamma potently stimulat …
Biomimetic nanovaccines employing cancer cell membranes display inherent biocompatibility and stimulate T-cell responses again …
pH-Responsive STING-Activating DNA Nanovaccines for Cancer Immunotherapy.
Zhang Y, Shen T, Zhou S, Wang W, Lin S, Zhu G. Zhang Y, et al. Adv Ther (Weinh). 2020 Sep;3(9):2000083. doi: 10.1002/adtp.202000083. Epub 2020 Jun 8. Adv Ther (Weinh). 2020. PMID: 34337143 Free PMC article.
Here, STING-activating DNA nanovaccines (STING-NVs) are developed, which biostabilize, deliver, and conditionally release CDG in the endosome of immune cells, elicit potent antitumor immune responses in murine and human immune cells, ameliorate immunosuppress …
Here, STING-activating DNA nanovaccines (STING-NVs) are developed, which biostabilize, deliver, and conditionally relea …
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
Jiang X, Wang J, Zheng X, Liu Z, Zhang X, Li Y, Wilhelm J, Cao J, Huang G, Zhang J, Sumer B, Lea J, Lu Z, Gao J, Luo M. Jiang X, et al. J Immunother Cancer. 2022 May;10(5):e003960. doi: 10.1136/jitc-2021-003960. J Immunother Cancer. 2022. PMID: 35623658 Free PMC article.
An optimized vaccine approach to induce antigen-specific T cells that can perform robust tumor infiltration is important to accelerate their clinical translation. We previously developed a STING-activating PC7A nanovaccine that produces a strong anti-tumor T …
An optimized vaccine approach to induce antigen-specific T cells that can perform robust tumor infiltration is important to accelerate their …
Engineered virus-mimicking nanovaccine with lymph node-tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy.
Wang Z, Liu S, Ming R, Wang W, Wang C, Li C, Yang J, Zhang F, Lu G, Mei L, Huang LL. Wang Z, et al. J Control Release. 2025 Feb 10;378:416-427. doi: 10.1016/j.jconrel.2024.12.034. Epub 2024 Dec 20. J Control Release. 2025. PMID: 39694072
Cancer vaccines have garnered considerable interest for cancer immunotherapy. However, their effectiveness is limited by inadequate proliferation, activation, and tumor infiltration of cytotoxic T lymphocytes (CTLs). ...The coactivation of the immune response …
Cancer vaccines have garnered considerable interest for cancer immunotherapy. However, their effectiveness is limited b …
Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy.
Luo M, Liu Z, Zhang X, Han C, Samandi LZ, Dong C, Sumer BD, Lea J, Fu YX, Gao J. Luo M, et al. J Control Release. 2019 Apr 28;300:154-160. doi: 10.1016/j.jconrel.2019.02.036. Epub 2019 Mar 4. J Control Release. 2019. PMID: 30844475
Solid cancers are able to escape immune surveillance and are resistant to current treatment in immunotherapy. ...STING-targeted activation is extensively investigated as a new strategy for cancer therapy. Previously, we reported a safe and efficacious STIN …
Solid cancers are able to escape immune surveillance and are resistant to current treatment in immunotherapy. ...STING-targete …
A STING-activating biomimetic mineralized nanovaccine triggers robust anti-tumor immunity.
Tuo S, Wang Y, Tian M, Su L, Dong J, Lv K, He W, Feng Q, Chen S, Dong D, Li X, Zhong K, Zhang Y, Kong B, He L. Tuo S, et al. Cancer Immunol Immunother. 2026 Mar 7;75(4):95. doi: 10.1007/s00262-026-04320-3. Cancer Immunol Immunother. 2026. PMID: 41793474 Free PMC article.
In this study, we introduce a novel STING-activating tumor nanovaccine, designated OVA/Tp@Mn-DNA. The preparation of OVA/Tp@Mn-DNA nanovaccine is a straightforward process involving the self-assembly of Mn(2+) and DNA molecules into nanospheres, which …
In this study, we introduce a novel STING-activating tumor nanovaccine, designated OVA/Tp@Mn-DNA. The preparation of OV …
Human serum albumin as the carrier to fabricate STING-activating peptide nanovaccine for antitumor immunotherapy.
Zheng A, Ning Z, Wang X, Li Z, Sun Y, Wu M, Zhang D, Liu X, Chen J, Zeng Y. Zheng A, et al. Mater Today Bio. 2024 Jan 14;25:100955. doi: 10.1016/j.mtbio.2024.100955. eCollection 2024 Apr. Mater Today Bio. 2024. PMID: 38312800 Free PMC article.
However, when used alone, they still suffer from significant challenges including poor stability and immunogenicity as well as the low delivery efficiency, leading to limited therapeutic success. Herein, the STING-activating peptide nanovaccine based on human …
However, when used alone, they still suffer from significant challenges including poor stability and immunogenicity as well as the low deliv …
15 results